In HER2+ breast cancer, mAbs have become the frontline standard of care, outperforming HER2-specific small molecule inhibitors and achieving excellent responses with modest toxicities [37], which require IgG–FcγR interaction [38]. This evidence concerns the gene ERBB2 and breast carcinoma.